0
Industry
Geography
Report Type
Price
Publication date
Published Date
  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Pulmonary Sarcoidosis – Drugs In Development, 2024

    Empower your strategies with our Pulmonary Sarcoidosis – Drugs In Development, 2024 report and make more profitable business decisions. Pulmonary Sarcoidosis is a rare inflammatory disease that affects the multi-organs predominantly lungs and intrathoracic lymph nodes. It is characterized by the presence of granulomas in which group of cells form clusters of inflamed tissue. Younger and middle-aged groups are commonly affected and there is no specific origin causing this condition. It is differentiated into five different stages from stage 0 to...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Thrombotic Microangiopathy – Drugs In Development, 2024

    Empower your strategies with our Thrombotic Microangiopathy – Drugs In Development, 2024 report and make more profitable business decisions. Thrombotic Microangiopathy is a life-threatening group of hematological diseases characterized by hemolytic anemia (destruction of red blood cells), thrombocytopenia, and microthrombi leading to ischemic tissue injury. In severe cases, TMA leads to kidney injury. Mutations in the ADAMTS13 gene and atypical hemolytic uremic syndrome cause TMA. It can also be caused by infectious diseases, blood-borne diseases, drug-induced etc. Complete blood count to...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Gastroparesis – Drugs In Development, 2024

    Empower your strategies with our Gastroparesis – Drugs In Development, 2024 report and make more profitable business decisions. Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from stomach to small intestine, even though there is no blockage in the stomach or intestines. The symptoms of gastroparesis may include feeling full shortly after starting a meal, feeling full long after eating a meal, nausea, and vomiting. Diabetes is the most common known cause...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Cystitis – Drugs In Development, 2024

    Empower your strategies with our Cystitis – Drugs In Development, 2024 report and make more profitable business decisions. Cystitis is a bacterial infection of the bladder or lower urinary tract. It is caused by germs, usually bacteria that enter the urethra and then the bladder. These bacteria can lead to infection, most commonly in the bladder. Cystitis also may occur as a reaction to certain drugs or radiation therapy. Symptoms from a lower urinary tract infection include pain with urination, frequent...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Prurigo – Drugs In Development, 2024

    Empower your strategies with our Prurigo – Drugs In Development, 2024 report and make more profitable business decisions. Prurigo nodularis (PN) is a skin disease characterized by pruritic (itchy) nodules that usually appear on the arms or legs. It is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques, and nodules commonly located on the extensor surfaces of the extremities. The exact cause of PN is unknown. The condition may be...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Achondroplasia – Drugs In Development, 2024

    Empower your strategies with our Achondroplasia – Drugs In Development, 2024 report and make more profitable business decisions. Achondroplasia is a bone growth disorder that causes disproportionate dwarfism. This is caused by mutations in the FGFR3 gene. Symptoms include decreased muscle tone, apnea, hydrocephalus, short arms and legs, disproportionately large head compared to the body, and kyphosis. Treatment includes growth hormones. The Achondroplasia drugs in development market research report provide comprehensive information on the therapeutics under development for Achondroplasia, complete with...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Hyperinsulinemia – Drugs In Development, 2024

    Empower your strategies with our Hyperinsulinemia – Drugs In Development, 2024 report and make more profitable business decisions. Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. Insulin resistance is the primary cause of hyperinsulinemia. Symptoms include weight gain, feeling anxious, fatigue, and frequent hunger. Risk factors include higher triglyceride levels, high uric acid, weight gain, type 2 diabetes, and hypertension. Treatment includes insulin secretion inhibiting agents, diet,...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Hypoparathyroidism – Drugs In Development, 2024

    Empower your strategies with our Hypoparathyroidism – Drugs In Development, 2024 report and make more profitable business decisions. Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction) and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Retinoblastoma – Drugs In Development, 2024

    Empower your strategies with our Retinoblastoma – Drugs In Development, 2024 report and make more profitable business decisions. Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris, and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy, and surgery. The Retinoblastoma drugs in development market research report provide comprehensive information on the therapeutics...

  • Product Insights

    New
    $2,000 | June 2024
    Product Insights
    New

    Smallpox – Drugs In Development, 2024

    Empower your strategies with our Smallpox – Drugs In Development, 2024 report and make more profitable business decisions. Smallpox was an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain, and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat....

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.